Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 37

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 37
---
 to our existing shareholders and/or increased fixed payment obligations. Furthermore, these securities may have
rights senior to those of our Ordinary Shares and could contain covenants that would restrict our operations and potentially impair our
competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events
could significantly harm our business, financial condition and prospects.

Our forecast of the period
of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks
and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this
“Risk Factors” section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize
our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly
faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control.
Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

| • | any acquisitions and the commercialization of other assets, including licensed assets; |

| • | the initiation, progress, timing, costs and results of clinical trials for any product candidates we advance 
 to clinical trials;                                                                                          |

| • | the attainment of milestones and the need to make any royalty payments on any of our product candidates 
 or any other future product candidates;                                                                 |

| • | the number and characteristics of product candidates we in-license or acquire and develop; |

| • | the outcome, timing and cost of regulatory approvals by the EMA, the MHRA, the FDA and any other comparable                              
 foreign regulatory authorities, including the potential for such regulatory authorities to require that we perform more studies, or more 
 costly studies, than those we currently expect;                                                                                          |

| • | the cost of filing, prosecuting, defending and enforcing any patent claims or other intellectual property 
 rights; and                                                                                               |

| • | the effect of competing technological and market developments. |

Further, our forecast also
does not reflect the possibility that we may not be able to access a portion of our existing cash, cash equivalents and investments due
to market conditions. For example, on March 10, 2023, the United States Federal Deposit Insurance Corporation took control and was appointed
receiver of